
ANI Pharmaceuticals, Inc.
ANIP
ANIP: ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
moreShow ANIP Financials
Recent trades of ANIP by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by ANIP's directors and management
Government lobbying spending instances
-
$10,000 Jul 19, 2022 Issue: Medical/Disease Research/Clinical Labs Health Issues
-
$10,000 Apr 18, 2022 Issue: Medical/Disease Research/Clinical Labs Health Issues
-
$40,000 Apr 22, 2019 Issue: Health Issues Medical/Disease Research/Clinical Labs Pharmacy
-
$40,000 Jan 17, 2019 Issue: Pharmacy Medical/Disease Research/Clinical Labs Health Issues
-
$40,000 Oct 22, 2018 Issue: Pharmacy Health Issues Medical/Disease Research/Clinical Labs
-
$30,000 Jul 19, 2018 Issue: Medical/Disease Research/Clinical Labs Pharmacy Health Issues
-
$20,000 Apr 20, 2018 Issue: Pharmacy Health Issues Medical/Disease Research/Clinical Labs
New patents grants
Federal grants, loans, and purchases
Followers on ANIP's company Twitter account
Number of mentions of ANIP in WallStreetBets Daily Discussion
Recent insights relating to ANIP
Recent picks made for ANIP stock on CNBC
ETFs with the largest estimated holdings in ANIP
Flights by private jets registered to ANIP